Kiora Pharmaceuticals Inc KPRX
We take great care to ensure that the data presented and summarized in this overview for KIORA PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in KPRX
Top Purchases
Top Sells
About KPRX
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.
Insider Transactions at KPRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Melissa Tosca EVP Finance |
BUY
Open market or private purchase
|
Direct |
100
+2.45%
|
$500
$5.25 P/Share
|
|
Jun 14
2024
|
Eric Joseph Daniels Chief Development Officer |
BUY
Open market or private purchase
|
Direct |
1,431
+11.31%
|
$7,155
$5.29 P/Share
|
|
Jun 13
2024
|
Brian M. Strem President and CEO |
BUY
Open market or private purchase
|
Direct |
3,000
+17.11%
|
$15,000
$5.0 P/Share
|
|
Jun 13
2024
|
Erin Parsons Director |
BUY
Open market or private purchase
|
Indirect |
5,260
+50.0%
|
$21,040
$4.88 P/Share
|
|
Sep 29
2023
|
Brian M. Strem President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+41.95%
|
-
|
|
Sep 29
2023
|
Eric Joseph Daniels Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+41.44%
|
-
|
|
Sep 29
2023
|
Melissa Tosca EVP Finance |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+46.23%
|
-
|
|
Mar 03
2023
|
Eric Joseph Daniels Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,600
+37.65%
|
-
|
|
Mar 03
2023
|
Brian M. Strem President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,600
+35.15%
|
$46,800
$3.83 P/Share
|
|
Mar 03
2023
|
Melissa Tosca EVP Finance |
BUY
Grant, award, or other acquisition
|
Direct |
2,400
+24.49%
|
-
|
|
Oct 21
2022
|
Brian M. Strem President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+48.67%
|
-
|
|
Oct 21
2022
|
Melissa Tosca EVP Finance |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Oct 21
2022
|
Eric Joseph Daniels Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+49.41%
|
-
|
|
Feb 10
2022
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
108
-0.47%
|
$0
$0.69 P/Share
|
|
Jan 05
2022
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
326
-0.48%
|
$326
$1.08 P/Share
|
|
Jan 05
2022
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
114
-0.5%
|
$114
$1.08 P/Share
|
|
Dec 07
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
91
-0.39%
|
$91
$1.3 P/Share
|
|
Dec 07
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-0.4%
|
$273
$1.3 P/Share
|
|
Nov 18
2021
|
Brian M. Strem President and CEO |
BUY
Open market or private purchase
|
Direct |
17,853
+39.48%
|
$17,853
$1.41 P/Share
|
|
Nov 02
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-0.36%
|
$83
$1.98 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 168K shares |
|---|---|
| Open market or private purchase | 9.79K shares |